for proposals to increase access to TB, HIV and malaria medicines, treatment and diagnostics in low
and middle-income countries — deadline 22
If you are a
researcher, NGO, Product Development Partnership,
or other group or individual working in TB, HIV or malaria, the deadline is
quickly approaching to submit a letter of intent (LOI) explaining your project
proposal to UNITAID.
UNITAID is an international facility that seeks to provide
diagnostics and pharmaceuticals for AIDS, tuberculosis and malaria to
developing countries at deeply reduced prices through market interventions.
Launched on the government of France’s initiative, it is funded by innovative
financing mechanisms — more than half the money comes from an airline ticket levy
in participating countries (Cameroon, Chile, Congo, France, Madagascar, Mali,
Mauritius, Niger and the Republic of Korea), and voluntary donations from airline
travellers in other countries.
achievements have been to map the markets for antiretroviral products, project
future demand and to work with the Clinton HIV/AIDS Initiative to help
manufacturers re-engineer processes and supply chains to bring down prices and
project future volumes.
ACTION (ACTION to
Control TB Internationally) has put out an alert to TB researchers in particular.
ACTION states that to date, UNITAID has granted $240 million towards TB
projects, and that UNITAID is particularly interested in TB proposals that seek
Improve diagnostic tools for MDR-TB, primarily through price reductions of GeneXpert, and
developing linkages between new diagnostics and medicines markets.
Develop quality assurance and delivery mechanisms for first line
anti-TB drugs to improve
standards and regulation, get rid of poor quality drugs, and prevent country
Increase affordability and accessibility to second-line anti-TB drugs by reinforcing supply chain management and
increasing diagnostics to drive demand.
Address pediatric TB pharmaceuticals and diagnostics through developing a fixed-dose combination
(FDC) drug for children, new diagnostics for pediatric TB, and improving the
supply of currently available medication.
It is particularly
encouraging that UNITAID is looking at how it can influence the development of
a robust market for second-line TB drugs and for the diagnostics that will support the
development of that market.(The most recent edition of HATIP looks in detail at one element of that process, the introduction of the GeneXpert platform and the Xpert MTB/RIF test, which can both detect TB and rifampicin resistance).
Indeed UNITAID held
a meeting at the World Health Assembly in Geneva this week in order to get
people talking about how the fragmented but very large markets for second-line
TB drugs in the BRICS countries (Brazil, Russia, India, China and South Africa)
can be brought together in order to deliver the same kinds of win-win
developments for patients and industry that have already occurred in HIV.
you access these funds?
consult the Guidelines, Application Form, and background invitation below
Act fast: the Deadline:
May 22, 2012
If the LOI is
accepted, UNITAID will contact applicants and ask them to submit a full
proposal in September 2012. Proposals will go through technical review in
committee and then to the UNITAID board for final review and a vote to approve
Contact: For further information, contact UNITAID
via email at the following address: firstname.lastname@example.org